PANTETHIN
D-pantethine anhydrous
CAS: 16816-67-4;138148-35-3
Molecular Formula: C22H42N4O8S2
PANTETHIN - Names and Identifiers
| Name | D-pantethine anhydrous |
| Synonyms | PANTETHIN Pantethine D-Pantethine lbfdisulfide d-(+)-3-dimethyl D-pantethine syrup d-pantethineanhydrous D-pantethine anhydrous bis(pantothenamidoethyl)disulfide d-bis(n-pantothenyl-beta-aminoethyl)disulfide butyramide,n,n'-(dithiobis(ethyleneiminocarbonylethylene))bis(2,4-dihydroxy-3, Butanamide, N,N-dithiobis2,1-ethanediylimino(3-oxo-3,1-propanediyl)bis2,4-dihydroxy-3,3-dimethyl-, (2R,2R)- N-(17,19-dihydroxy-18,18-dimethyl-3,12,16-trioxo-7,8-dithia-4,11,15-triazanonadec-1-yl)-2,4-dihydroxy-3,3-dimethylbutanamide (non-preferred name) (2R)-N-[(17R)-17,19-dihydroxy-18,18-dimethyl-3,12,16-trioxo-7,8-dithia-4,11,15-triazanonadec-1-yl]-2,4-dihydroxy-3,3-dimethylbutanamide (non-preferred name) |
| CAS | 16816-67-4 138148-35-3 |
| EINECS | 240-842-8 |
| InChI | InChI=1/C22H42N4O8S2/c1-21(2,13-27)17(31)19(33)25-7-5-15(29)23-9-11-35-36-12-10-24-16(30)6-8-26-20(34)18(32)22(3,4)14-28/h17-18,27-28,31-32H,5-14H2,1-4H3,(H,23,29)(H,24,30)(H,25,33)(H,26,34)/t17-,18-/m0/s1 |
PANTETHIN - Physico-chemical Properties
| Molecular Formula | C22H42N4O8S2 |
| Molar Mass | 554.72 |
| Density | 1.1949 (rough estimate) |
| Boling Point | 987.2±65.0 °C(Predicted) |
| Specific Rotation(α) | D27 +13.5° (c = 3.75 in water) |
| Flash Point | 550.8°C |
| Solubility | Methanol (Slightly), Water (Slightly) |
| Vapor Presure | 0mmHg at 25°C |
| Appearance | Colorless to pale yellow, transparent, viscous liquid |
| Color | Crystals from MeOH/Me2CO |
| pKa | 12.71±0.20(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Hygroscopic |
| Refractive Index | 1.6000 (estimate) |
| Physical and Chemical Properties | Colorless or yellowish viscous substance, soluble in water and ethanol, especially difficult to dissolve in ether, chloroform, acetone. The aqueous solution was neutral. Slightly bitter. FIG. 1 shows the molecular structure of panthioethylamine. |
| Use | This product is for scientific research only and shall not be used for other purposes. |
PANTETHIN - Risk and Safety
| WGK Germany | 3 |
| RTECS | ES4392700 |
| Toxicity | LD50 oral in rat: > 10gm/kg |
PANTETHIN - Reference Information
| Plant source: | Schisandra chinensis |
| pharmacological effects | pantothenate is an analog of pantothenic acid and a precursor of coenzyme a. it has the effects of enhancing lipid metabolism and reducing triglyceride and cholesterol. its pharmacological effects are as follows: ① it mainly reduces cholesterol levels by increasing the decomposition of cholesterol in low density lipoprotein (LDL) and very low density lipoprotein (VLDL). ② VLDL is converted into high density lipoprotein (HDL) by increasing the synthesis of apolipoprotein A- I and enhancing the activity of tissue lipase, thus increasing the content of HDL. ③It can also accelerate the β-oxidation process of fatty acids in the liver and arterial walls, prevent cholesterol deposition on the arterial walls, and promote the production of adrenal cortex hormones, promote intestinal peristalsis, and anti-platelet aggregation. Animal experiments have confirmed that it can promote the normal metabolism of blood lipids, improve fatty liver and alcoholic liver damage, and inhibit the formation of lipid peroxide and platelet aggregation. It also prevents the deposition of cholesterol in the blood vessel wall. It has been proved by clinical application at home and abroad that blood cholesterol can be reduced by 5.2% ~ 15.2%, triglyceride can be reduced by 23.6% ~ 31.7%, and high density lipoprotein can be increased by 10.0% ~ 20.5%. Domestic clinical observation lipid-lowering effective rate: cholesterol is 60%, triglyceride is 73.1%, and high-density lipoprotein is 59.1%. Panthioethylamine is a safe and effective lipid regulating drug. |
| pharmacokinetics | normal and diseased rats (arteriosclerosis, diabetes, ethanol fatty liver) were orally taken 200mg/kg1 times. the radioactive concentration in blood reached the peak value in normal rats at 16h and diseased rats at 16h, 8h and 24h respectively. Within 48 hours after normal rats were given this product, about 85% of the radioactivity was excreted with urine, feces and exhaled gas, and bile was almost not excreted. |
| clinical application | clinical application as a basic hypolipidemic drug to reduce plasma total cholesterol, triglyceride, LDL, VLDL and increase HDL. Its lipid-lowering effect is mild, long-lasting, and has small side effects. It can be combined with other lipid-lowering drugs to delay the development of atherosclerosis; prevent the formation of thrombosis and assist thrombolysis. The overall role is to prevent the occurrence and development of heart and cerebrovascular obstructive diseases. ① It is used to treat hyperlipidemia, fatty liver and alcoholic liver disease. ② prevention and treatment of lipid metabolism disorders, hypercholesterolemia, asthenic constipation, streptomycin and kanamycin side effects, improvement of platelet count and bleeding tendency in acute and chronic eczema and blood diseases. ③ pantothenic acid requirement increases, and supplement from insufficient dietary intake (including wasting diseases, hyperthyroidism, pregnant women and lactating women, etc.). ④ It can also be used as an adjuvant treatment for pantothenic acid deficiency and metabolic disorders, such as side effects caused by aminoglycosides, acute and chronic eczema, hyperthyroidism, etc. |
| drug interaction | 1. It can be combined with powerful lipid-lowering drugs such as lovastatin and fenofibrate to reduce drug dosage and side effects. 2. It can be combined with tissue plasminogen activator (TPA) and urokinase in antithrombotic therapy. 3. In the prevention of atherosclerosis, it can be combined with probucol. |
| adverse reactions | adverse reactions are mild, occasionally including loss of appetite, abdominal distension, nausea, vomiting, urticaria, etc. Sometimes mild diarrhea, soft stools, fatigue and transient increases in aminotransferase can be seen. Generally, no special treatment and withdrawal are required. |
| precautions | mild hyperlipidemia can be used alone, moderate and severe hyperlipidemia should be used in combination with other drugs. Check liver function before treatment, and check once every 4 weeks thereafter. The drug should be stopped when the transaminase rises. Use with caution in patients with hepatic insufficiency and pregnant women. Do not drink alcohol, tea, or coffee during treatment, so as not to reduce the efficacy. Liver function should be checked regularly for long-term medication. |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: Pantethine Visit Supplier Webpage Request for quotationCAS: 16816-67-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Pantethine Visit Supplier Webpage Request for quotationCAS: 16816-67-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History